Lyfebulb-Novo Nordisk Innovation Award 2017

Novo NordiskThe Lyfebulb-Novo Nordisk Innovation Summit 2017 will recognize and empower international Patient Entrepreneurs with big ideas that disrupt the future of diabetes management. Patient Entrepreneurs have a unique ability to create value-adding disease management solutions beyond therapy. The aim is to support patient-driven innovation and laser-focus on improving the quality of life for those living with diabetes.

Pitch Competition

The pitch competition brings to the stage emerging Patient Entrepreneurs to pitch their invention or idea to Lyfebulb founders, Novo Nordisk R&D device leadership, researchers and engineers, and venture capitalists. Contestants will respond to a round of Q&A by the judging panel. The top three outstanding Patient Entrepreneurs will receive monetary awards to further develop their ideas:
  • 1st Prize: 25,000USD
  • 2nd Prize: 15,000USD
  • 3rd Prize: 10,000USD

Benefits

National and international recognition: Visibility of the selected 10 finalists and the winner in particular.

Invitation to the Lyfebulb–Novo Nordisk Innovation Summit 2017 in Copenhagen as one of 10 Finalists.

  • Travel to and from, and accommodation in Copenhagen, Denmark during the Summit.
  • Opportunity to engage with Lyfebulb founders, Novo Nordisk device research leadership, researchers and engineers, and venture capitalists to interact and discuss how together we can disrupt the future of the management of diabetes.

The winner will be chosen by a judging panel made up of international representatives from the diabetes community.

Eligibility

  • You work on innovative ideas and concepts for better management of diabetes using consumer or medical devices or healthcare IT (drug only innovations are excluded).
  • You live with diabetes or have a close relative and/or loved one with diabetes.
  • You have the aspiration to develop your project and to deliver the benefit to others suffering from the same burden.
  • You have a registered company for developing and commercializing your idea and concepts that the prize money can be award too.
  • You can document that there is a sound scientific and medical rationale for the idea.
  • You have a strong business case behind the idea.

Application deadline is September 15th.

For further information and to apply, please visit:
http://lyfebulb.com/innovation-award/novo-nordisk-2017/

Related news article:

About Lyfebulb
Lyfebulb is a business focused on bridging patient communities with industry, and providing a strong voice to people living with chronic disease by empowering Patient Entrepreneurs. Our vision is to improve the quality of life of those living with diabetes and other chronic disease.

Lyfebulb was founded in 2014 and is headquartered in New York, NY.

About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity.

Headquartered in Denmark, Novo Nordisk employs approximately 42,000 people in 77 countries and markets its products in more than 165 countries.

Most Popular Now

73,000 Scientists collaborate over new COVID-19 Da…

More than 73,000 users collaborate on new online platform set up by the European Open Science Cloud Initiative, where scientists share COVID-19 data and accelerate our un...

Pfizer and BioNTech announce data from preclinical…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced preliminary preclinical data in mouse and non-human primate models from their BNT162b2 mRNA-based v...

Antiviral used to treat cat coronavirus also works…

Researchers at the University of Alberta are preparing to launch clinical trials of a drug used to cure a deadly disease caused by a coronavirus in cats that they expect ...

Search for COVID-19 drugs boosted by SARS discover…

An extensive search and testing of current drugs and drug-like compounds has revealed compounds previously developed to fight SARS might also work against COVID-19. Us...

Sinovac reports preliminary Phase I/II results of …

Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced that the inactivated COVID-19 vaccin...

COVID-19 study links strict social distancing to m…

Using public transportation, visiting a place of worship, or otherwise traveling from the home is associated with a significantly higher likelihood of testing positive wi...

CureVac expected to receive up to 252 million euro…

CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) in clinical trials...

Phase I clinical trial initiated for monoclonal an…

The first participants have been dosed in a Phase I trial of AZD7442, a combination of two monoclonal antibodies (mAbs) in development for the prevention and treatment of...

Vitamin D deficiency may raise risk of getting COV…

In a retrospective study of patients tested for COVID-19, researchers at the University of Chicago Medicine found an association between vitamin D deficiency and the like...

Europe's largest initiative launches to accelerate…

CARE (Corona Accelerated R&D in Europe) a new consortium supported by the Innovative Medicines Initiative (IMI) public-private partnership announced its launch to acceler...

Blocking cellular communication stops SARS-CoV-2

In the transmission of signals within the cell which, for example, stimulate cell growth or trigger metabolic processes, phosphate groups play an important biochemical ro...

Improving FDA's COVID-19 vaccine authorization and…

On March 28, the Food and Drug Administration (FDA) exercised its Emergency Use Authorization (EUA) authority to allow the use of hydroxychloroquine for the treatment of ...